Quantitative analysis of mitoxantrone by surface-enhanced resonance Raman scattering.
Mitoxantrone is an anticancer agent for which it is important to know the concentration in blood during therapy. Current methods of analysis are cumbersome, requiring a pretreatment stage. A method based on surface-enhanced resonance Raman scattering (SERRS) has been developed using a flow cell and silver colloid as the SERRS substrate. It is simple, sensitive, fast, and reliable. Both blood plasma and serum can be analyzed directly, but fresh serum is preferred here due to reduced fluorescence in the clinical samples available. Fluorescence is reduced further by the dilution of the serum in the flow cell and by quenching by the silver of surface-adsorbed material. The effectiveness of the latter process is dependent on the contact time between the serum and the silver. The linear range encompasses the range of concentrations detected previously in patient samples using HPLC methods. In a comparative study of a series of samples taken from a patient at different times, there is good agreement between the results obtained by HPLC and SERRS with no significant difference between them at the 95% limit. The limit of detection in serum using the final optimized procedure for SERRS was 4.0 x 10(-11) M (0.02 ng/mL) mitoxantrone. The ease with which the SERRS analysis can be carried out makes it the preferred choice of technique for mitoxantrone analysis.
Department of Pure and Applied Chemistry, Strathclyde University, Glasgow, Scotland.
Clare
C
McLaughlin
Donald
D
MacMillan
Colin
C
McCardle
W Ewen
WE
Smith
D000970:Antineoplastic Agents / Q000032:analysis* / Q000097:blood; D002138:Calibration; D002851:Chromatography, High Pressure Liquid; D006801:Humans; D007202:Indicators and Reagents; D008942:Mitoxantrone / Q000032:analysis* / Q000097:blood; D020349:Surface Plasmon Resonance
D000970:Antineoplastic Agents; D007202:Indicators and Reagents; D008942:Mitoxantrone